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PSY32
THE COST-EFFECTIVENESS OF ELTROMBOPAG FOR THE TREATMENT 
OF CHRONIC ADULT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) 
IN IRELAND
Hanley RM1, Redmond S1, Thompson G2
1GlaxoSmithKline, Dublin, Ireland; 2GlaxoSmithKline, Uxbridge, UK
OBJECTIVES: Immune thrombocytopenia (ITP) is a rare autoimmune disorder char-
acterised by low platelet counts resulting in symptoms that are usually minor, e.g. 
petechiae. However, patients with very low platelet counts face the risk of serious, 
but rare, bleeds, e.g. intracranial hemorrhage. The study objective was to estimate the 
cost-effectiveness of treating two groups of chronic adult ITP patients (refractory to 
splenectomy and where splenectomy is contraindicted) with oral eltrombopag versus 
romiplostim or rituximab from an Irish health care payer perspective. METHODS: A 
Markov model with a four week model cycle, two year time horizon and seven health 
states was used. In one arm, patients were treated with eltrombopag and in the other 
romiplostim or rituximab. Patients began in either the ‘controlled platelet’ or ‘uncon-
trolled platelet’ health states. Response rates from clinical trials (eltrombopag and 
romiplostim) and a published literature review (rituximab) determined whether 
patients were controlled or not. Controlled patients experienced a higher level of utility 
and lower risk of transitioning to bleed health states. Utilities (using the SF-36v2) for 
controlled/uncontrolled platelet levels were from the eltrombopag pivotal trial, RAISE. 
Utility for bleeds and costs were taken from the literature. Costs and beneﬁ ts were 
discounted by 4%. RESULTS: The model estimated that eltrombopag dominates 
romiplostim, i.e. cost savings of c13,000 and c18,000 with an incremental QALY of 
0.1 and 0.03 for patients who are refractory to splenectomy and where splenectomy 
is contraindicated respectively. This result was driven by the fact that eltrombopag is 
less expensive, does not incur wastage or administration costs and has slightly better 
durable response rates compared to romiplostim. Eltrombopag is not cost-effective 
compared to rituximab for both groups of patients because rituximab is signiﬁ cantly 
less costly than eltrombopag with comparable response rates. CONCLUSIONS: The 
economic model showed that eltrombopag dominates romiplostim but is not cost-
effective versus rituximab.
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EARLY STAGE ECONOMIC EVALUATION OF PHARMACOGENOMIC-
BASED DIAGNOSTICS IN CHRONIC MYELOID LEUKEMIA
Gaultney J1, Sanhueza E2, Janssen JJWM3, Redekop WK1, Uyl-De Groot C1
1Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands; 
2Facultad de Medicina Universidad Católica de Chile, Santiago, Chile; 3VU University Medical 
Center, Amsterdam, The Netherlands
OBJECTIVES: Uncertainty regarding the effectiveness of tyrosine kinase inhibitors 
(TKIs) for treatment of chronic myeloid leukemia (CML) has resulted in difﬁ culty for 
some appraisal committees to recommend second-line TKIs. Implementation of phar-
macogenomic-based diagnostics may facilitate individualized treatment with TKIs and 
improve overall treatment effectiveness. The objective of this economic evaluation was 
to estimate the potential cost-effectiveness of a companion diagnostic that predicts 
treatment response in CML patients eligible for dasatinib and nilotinib. METHODS: 
A decision analytic model was created to assess the cost-effectiveness of individualized 
treatment with dasatinib and nilotinib using a companion diagnostic test relative to 
current care (i.e., treat all patients with dasatinib until progression or no response, 
then treat with nilotinib). Transition probabilities and utility values were taken from 
published RCTs. The cost analysis included costs of treatment, response monitoring 
and the companion diagnostic. Scenario analyses were conducted to assess the impact 
of unavailable or highly uncertain values. RESULTS: Total costs and effects for the 
base-case analysis were c99,011 and 1.84 progression-free LYs (PF-LYs) and 1.63 
QALYs with the companion diagnostic strategy after a 2-year time horizon. In the 
current care situation, total costs and effects were c100,904 and 1.74 PF-LYs and 
1.61 QALYs. The companion diagnostic was the dominant strategy with a savings of 
approximately c4,000/PF-LY or c2,000/QALY. Scenario analyses revealed that the 
cost-effectiveness of the companion diagnostic is sensitive to time to response, time to 
progression and comparative effectiveness between dasatinib and nilotinib. CONCLU-
SIONS: Treatment of CML patients eligible for second-line TKIs using a companion 
diagnostic may be cost-effective. More precise estimates for uncertain or unavailable 
parameters should be incorporated when available. This case demonstrates the use of 
economic evaluation methods at early stages of technology development for internal 
decision-making and communicating the potential value of pharmacogenomic-based 
diagnostics to stakeholders.
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COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) 
COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH 
CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN
Hertel N1, Ikenberg R1, Fricke FU1, Liedgens H2
1IMS Health GmbH & Co. OHG, Nuremberg, Germany; 2Gruenenthal GmbH, Aachen, 
Germany
OBJECTIVES: To assess the cost-effectiveness of tapentadol compared to oxycodone 
and morphine as 1st line strong opioid therapy in chronic non-cancer pain (CNCP) 
patients in Sweden. METHODS: A Markov transition state model over one year with 
cycle times of one month was built. Four health states were deﬁ ned: ‘occurrence of 
adverse events (AEs) with need for medical treatment’, ‘withdrawal due to AEs’, 
‘response to therapy’ and ‘death’. If patients did not adequately respond to tapentadol 
or comparators or withdrew, switching to alternative 2nd line opioid (oxycodone, 
morphine or transdermal fentanyl) was considered. After initiating 3rd line therapy, 
patients could stay on this therapy or die according to morbidity rate. Data regarding 
efﬁ cacy, tolerability and utility values (EQ-5D) were derived from clinical trials and 
published literature. Switch rates to subsequent opioid therapies and resource con-
sumption were estimated by clinical experts. Costs were calculated from the societal 
perspective. Direct costs were calculated based on ofﬁ cial Swedish prices/tariffs, indi-
rect costs were calculated based on ﬁ gures obtained from the literature and current 
wage rates. Costs and beneﬁ ts were not discounted in base-case calculation. Impact 
of selected parameters on the results was evaluated in one-way sensitivity analyses 
(OWSA). RESULTS: Mean annual total costs per patient amount to 242,583 SEK 
(Swedish krona) for tapentadol vs. 247,813 SEK for oxycodone and 246,093 SEK for 
morphine. Tapentadol generates 0.4712 QALYs compared to 0.4518 QALYs for 
oxycodone and 0.4535 QALYs for morphine. More QALYs generated in the model 
reﬂ ect tapentadol’s better tolerability proﬁ le than comparators. Cost parameter com-
prising physician visits, co-medications and non-drug therapy costs revealed highest 
impact in OWSA. CONCLUSIONS: Tapentadol, once approved, will generate more 
QALYs at lower costs than oxycodone and morphine. Tapentadol appears to be the 
favourable treatment option in the 1st line therapy of CNCP patients in Sweden from 
a societal perspective.
PSY35
THE COST-EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF 
FIBROMYALGIA IN THE UNITED STATES
Beard S1, Le TK2, Zhao Y2, Roskell N3
1RTI Health Solutions, Shefﬁ eld, UK; 2Eli Lilly & Company, Indianapolis, IN, USA; 3RTI Health 
Solutions, Manchester, UK
OBJECTIVES: To evaluate the cost-effectiveness of duloxetine for the management 
of ﬁ bromyalgia assessed from the perspective of a health care payer in the United 
States. METHODS: A Markov model was used to evaluate the economic and clinical 
advantages in controlling ﬁ bromyalgia pain symptoms, considering duloxetine as an 
additional treatment option. The standard treatment sequence was deﬁ ned based on 
clinical guidelines including tricyclic antidepressants (TCAs), second-generation anti-
depressants (based on SNRIs), anticonvulsants, and opioid therapies. The model 
included 2 levels of pain response (a ≥30% and ≥50% change from baseline, using a 
standard 11-point severity scale). Clinical efﬁ cacy and discontinuation data were taken 
from a systematic literature review and mixed treatment comparison, including both 
placebo and active controlled trials. Utility data were linked to pain severity using 
trial-based EQ5D data. Discounting was applied at 3.0% per year. RESULTS: The 
introduction of duloxetine resulted in additional symptom-controlled months (SCMs), 
deﬁ ned as the amount of time at a ≥30% response level, and quality-adjusted life-years 
(QALYs), over a 2-year time horizon. First-line treatment resulted in an additional 
665 SCMs and 12.3 QALYs, with a cost of $582,911 ($877 per SCM and $47,560 
per QALY). Second-line treatment resulted in an additional 460 SCMs and 8.7 
QALYs, with a cost of $143,752 ($312 per SMC and $16,565 per QALY). a cost-
effectiveness frontier analysis suggested that second-line duloxetine is likely to be the 
most cost-effective option, however, in sensitivity analyses, the cost-effectiveness of 
ﬁ rst-line duloxetine improved when assumptions around continued treatment switch-
ing for long-term drop-outs were relaxed. CONCLUSIONS: There is currently a 
signiﬁ cant unmet need for patients with poorly controlled ﬁ bromyalgia where pain is 
a predominant symptom. These analyses show that the introduction of duloxetine into 
the standard treatment sequence for ﬁ bromyalgia can provide additional patient 
beneﬁ ts, which are cost-effective when compared to commonly adopted thresholds.
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FOR THE TREATMENT OF SEVERE HEMOPHILIA A
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1Baxter Healthcare SA, Zurich, Switzerland; 2London School of Hygiene and Tropical 
Medicine, London, UK
OBJECTIVES: The objective of this analysis was to understand the economic conse-
quences of different products in primary prophylaxis in severe hemophilia A patients. 
Miners’ (2002, 2009) hemophilia economic Markov model was revised to compare 
two different factor VIII products—a full-length recombinant FVIII (Advate) and a B 
domain-deleted recombinant FVIII (BDDrFVIII) (Refacto AF). Based on documented 
differences in half life in a pharmacokinetic cross-over license study [1] with results 
submitted to EMA[2], this research evaluated the amount of clotting factor required 
to maintain the patient factor VIII trough levels above 1%. If a product has a shorter 
half-life, more clotting factor is required to prevent factor VIII levels falling below the 
minimum trough level. METHODS: The same basic model structure of Miners’ 
hemophilia economic Markov model was used to analyze the effects of differences in 
half-life in an Italian economic country setting, full-length recombinant FVIII (Advate) 
half-life 13.3 hours at a list price of c0.75 per IU versus BDDrFVIII (Refacto AF) 
half-life 11.2 hours at a list price of c0.69 per IU. The model considers the amount 
of factor required to prevent trough clotting factor levels from falling below 1%. 
RESULTS: The analysis estimated that the mean expected, discounted lifetime (70 
years) cost of primary prophylaxis in a severe hemophilia A patient was c0.88 million 
less using full length recombinant FVIII (Advate) when compared to a BDDrFVIII 
(Refacto AF), assuming a 2.1 hour shorter half-life; i.e. equal to over c12,500 in cost 
savings per patient per year. CONCLUSIONS: This analysis shows that prophylaxis 
therapy using full-length recombinant FVIII (Advate) may be cost saving compared to 
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BDDrFVIII (Refacto AF) based on the difference in half-life reported, even if BDDrF-
VIII has a lower price per IU. [1] Recht et al. Hemophilia 2009:1–12; [2] EMA 
Assessment report Refacto AF. London March 2009. http://www.ema.europa.eu/
humandocs/PDFs/EPAR/Refacto/refactoaf-H-232-II-59-68-AR.pdf
PSY37
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF OROS 
HYDROMORPHONE IN PATIENTS WITH CHRONIC CANCER PAIN 
FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Fernandes RA1, Takemoto ML1, Guerra FC1, Passos RB1, Pereira ML2, Morais AD2
1ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2Janssen-Cilag, São Paulo, SP, 
Brazil
OBJECTIVES: To conduct cost-effectiveness and budget impact analysis (BIA) of 
OROS hydromorphone versus CR morphine and CR oxycodone for moderate to 
severe cancer pain from the public payer perspective in Brazil. METHODS: A decision 
tree followed by a Markov Model with a 12 month time horizon was developed with 
data from the Phase III trial Hanna 2008. The achievement of mild pain (worst pain 
scores < 4) was considered as outcome. Only direct medical costs were considered and 
unit costs were obtained from Brazilian ofﬁ cial lists. For the BIA, 10% of currently 
used CR morphine daily doses was substituted for equivalent OROS hydromorphone 
doses. The same rational was adopted for CR oxycodone comparison. Univariate 
deterministic sensitivity analyses showed that the results remained consistent through 
model parameters variation. RESULTS: OROS hydromorphone showed 1.66 addi-
tional months in mild pain per patient per year when compared to both CR morphine 
and CR oxycodone. Annual treatment costs were 2.401 BRL, 1.256 BRL and 5.114 
BRL for OROS hydromorphone, CR morphine and CR oxycodone respectively. The 
incremental cost-effectiveness ratio was 689 BRL per additional month in mild pain 
per patient per year, when OROS hydromorphone was compared to CR morphine. 
Versus CR oxycodone, OROS hydromorphone was more effective with fewer costs, 
being cost saving (ICER -1,634 BRL). BIA results showed that the substitution of 10% 
of current utilization of CR morphine for OROS hydromorphone and CR oxycodone 
would result in a budgetary impact of 118,722 BRL and 347,295 BRL, respectively. 
CONCLUSIONS: OROS hydromorphone is cost saving when compared to CR oxy-
codone and is more cost-effective than CR oxycodone when both are compared to 
the current scenario of chronic cancer pain treatment with CR morphine, with a lower 
budgetary impact.
PSY38
COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS 
FROM THE UK PAYER PERSPECTIVE
Muszbek N1, Punekar Y2, Buchanan J3, Prasad M4, Vioix H1, Brown R1
1United BioSource Corporation, London, UK; 2Schering Plough, Welwyn Garden City, UK; 
3Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA; 4Merck & Co, 
Kenilworth, NJ, USA
OBJECTIVES: Golimumab is a novel TNF-α inhibitor for treatment of patients with 
severe active ankylosing spondylitis (AS). This study evaluated the cost-effectiveness 
of golimumab and its appropriate comparators in the treatment of AS from UK 
National Health Service perspective. METHODS: A Markov model with an initial 
decision tree was developed to simulate the progression of a hypothetical cohort of 
active AS patients for 20 years. The primary outcome measure was quality-adjusted 
life-years (QALYs) estimated using Bath Ankylosing Spondilytis Functional Index 
(BASFI) whereas the primary response measure was ≥50% improvement in Bath 
Ankylosing Spondilytis Disease Activity Index (BASDAI) at 12 weeks. Direct costs 
including medication costs and AS management costs were included. Golimumab was 
compared with conventional treatment and other TNF-α inhibitors. Costs and out-
comes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were superior to 
conventional treatment and comparable to each other on BASDAI response. The 
incremental cost-effectiveness ratio (ICER) for golimumab was £15,353 per QALY 
compared to conventional treatment. The probability of golimumab being cost-effec-
tive at a threshold of £30,000/QALY was 92%. Compared to etanercept and adali-
mumab, golimumab generated marginally more QALYs at marginally more costs. 
CONCLUSIONS: Golimumab may be considered as a cost-effective treatment alterna-
tive for patients with AS. With comparable costs and efﬁ cacy to other TNF-α inhibi-
tors, golimumab’s position in the treatment pathway is likely to be driven by patient 
and physician choice.
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REAL-WORLD COST-EFFECTIVENESS OF BORTEZOMIB IN RELAPSED 
OR REFRACTORY MULTIPLE MYELOMA IN THE NETHERLANDS
Gaultney J1, Franken M1, Huijgens PC2, Sonneveld P3, Uyl-De Groot C1, Redekop WK1
1Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands; 2VU 
University Medical Center, Amsterdam, The Netherlands; 3Erasmus University Medical 
Center, Rotterdam, The Netherlands
OBJECTIVES: The Dutch reimbursement policy for expensive inpatient medicines 
requires outcomes research after four years of temporary reimbursement. Based on a 
retrospective study, we explored the cost-effectiveness of bortezomib for relapsed/
refractory multiple myeloma in Dutch daily practice. METHODS: Detailed clinical 
data from a real-world cohort of 72 patients treated with bortezomib and 67 patients 
never treated with bortezomib were collected from medical records. Validity of the 
incremental cost-effectiveness was assessed by comparing baseline prognosis between 
bortezomib and non-bortezomib patients. Clinical effectiveness was evaluated by 
comparing Kaplan-Meier survival estimates. Costs of resource use from a hospital 
perspective were based on patient-level data. RESULTS: Prognostic factors for bort-
ezomib patients were signiﬁ cantly different compared to non-bortezomib patients. 
Incremental analyses for bortezomib versus non-bortezomib patients were therefore 
not performed. Total mean costs and median survival from start of relapsed/refractory 
treatment for bortezomib patients were c84,042 and 33.2 months. Bortezomib 
accounted for 21% of total costs among these patients. For non-bortezomib patients, 
total mean costs and median survival from start of relapsed/refractory treatment were 
c54,435 and 21.6 months. The proportion of patients still in follow-up at the end of 
data collection was slightly higher in bortezomib versus non-bortezomib patients 
(51% vs. 46%). Total mean costs for bortezomib patients did not differ signiﬁ cantly 
when excluding patients still in follow-up. For non-bortezomib patients, total mean 
costs differed signiﬁ cantly when excluding patients still in follow-up, mainly due to 
high costs of lenalidomide treatment, stem cell transplants and inpatient hospital stays. 
CONCLUSIONS: Our real-world data challenged the assessment of the incremental 
cost-effectiveness of bortezomib versus other treatments in the indication of relapsed/
refractory multiple myeloma. It was possible to estimate the cost and effects for 
bortezomib patients in daily practice to determine the real-world value. Data synthesis 
incorporating effectiveness for the relevant comparator might facilitate estimation of 
a valid ICER.
PSY40
COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN 
REFRACTORY OUT-PATIENTS WITH NEUROPATIC PAIN FOLLOWED 
IN PRIMARY CARE SETTINGS
de Salas-Cansado M1, Pérez C2, Saldaña MT3, Navarro A4, Rejas J5
1Trial Form Support Spain, Madrid, Spain; 2Pain Clinic, Hospital de la Princesa, Madrid, Spain; 
3Primary Care Health Centre Raíces, Castrillón, Asturias, Spain; 4Primary Care Health Centre 
Puerta del Ángel, Madrid, Spain; 5Pﬁ zer España, Alcobendas/Madrid, Spain
OBJECTIVES: Estimate the cost-effectiveness of Pregabalin (PGB) versus Usual Care 
(UC) in refractory out-patients with Neuropathic Pain (NeP) treated according to 
usual medical practice in Primary Care settings (PCS) in Spain. METHODS: Data 
extracted from a 12-week non-interventional prospective study conducted to ascertain 
the cost of NeP were used. PGB naïve patients treated with UC or PGB, matched by 
age (+5 years), sex and pain intensity (+5 pts), refractory (≥40VAS-McGill) to previous 
treatment during the prior 6 months, were selected in a 1:1 ratio. Patients could switch 
to PGB (monotherapy/add-on) or to UC (non-narcotics, opiates, antidepressants and/
or anticonvulsants). Time horizon was 12 weeks. Effectiveness was quality-adjusted 
life-years (QALY) gain. Perspectives of the National Health Service (NHS) and society 
(2006) were included, and expressed as an incremental cost-effectiveness ratio (ICER). 
Bootstrapping techniques (10,000 re-samples) were used to obtain the probabilistic 
ICER, its 95% percentile conﬁ dence interval (CI) and the cost-effectiveness accept-
ability curve. RESULTS: A total of 160 patient-pairs were extracted. Compared with 
UC, PGB was associated with signiﬁ cantly higher QALY gain; 0.0374 ± 0.0367 vs. 
0.0224 ± 0.0313 (P < 0.001). Notably, although drug costs were higher for PGB (c251 
± 125 vs. c104 ± 121, P < 0.001), its QALY gain did not incur a higher overall total 
cost (c1335 ± 1302 vs. c1387 ± 1489; P = 0.587), nor higher health care costs (c529 
± 438 vs. c560 ± 672; p = 0.628). In fact, the ICER was dominant for total and health 
care costs, with CIs respectively, dominant-c17,268, and dominant-c6,508. ICER for 
drug costs was c10,672/QALY (dominant-c19,858). The 99% of the re-samples were 
below the threshold of c30,000/QALY. CONCLUSIONS: Versus usual care in the 
community medical setting, pregabalin is highly cost-effective in the treatment of 
refractory NeP patients. The high indirect costs and increased health care costs associ-
ated with the treatment of refractory patients, which offset higher cost of pregabalin, 
highlight the economic burden of the condition on society.
PSY41
COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN TWO LA 
COUNTRIES—COMPARISON WITH THE EUROPEAN EXPERIENCE
Alandete JC
Janssen-Cilag, Bogota, Colombia
OBJECTIVES: To evaluate cost-effectiveness of biologics used in patients with psoria-
sis in Colombia and Peru. METHODS: We estimated direct costs of etanercept, 
adalimumab, ustekinumab and inﬂ iximab based on their labels for ﬁ rst/induction year 
and second/maintenance year (EUR1 = COL$2340 = SOL$357). For etanercept we 
considered two induction schemes: 50 mg weekly 52 weeks-D1- and 100 mg 12 weeks 
followed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in 
Psoriasis Area and Severity Index-PASI 75- from meta-analysis presented by Hawkins 
et al. in the 14th International ISPOR: inﬂ iximab = 80%; ustekinumab = 69%; adali-
mumab = 59%; etanerceptD2- = 52%; etanerceptD1 = 39%. Inﬂ iximab and 
ustekinumab effectiveness were not signiﬁ cantly different. However, both were signiﬁ -
cantly superior to etanercept (D1 and D2). RESULTS: In Colombia, Ustekinumab was 
dominant (c29.012 in 2 years) generating cost savings of −c4.416 vs. etanerceptD1; 
−c7.411 vs. adalimumab; −c8.119 vs. etanerceptD2 and −c25,340 vs. inﬂ iximab; with 
higher or same effectiveness than the other biologics used in that country. In Peru, all 
the options were more effective and more costly than the standard of care (etaner-
ceptD1). The ICER per patient with PASI 75 of etanerceptD2, adalimumab, 
ustekinumab and inﬂ iximab, compared to etanerceptD1 were c21.654; c19,860, 
c13,036 and c29,008, respectively. Then, the efﬁ ciency frontier was formed by etan-
erceptD1, ustekinumab and inﬂ iximab. Given evidence shows the last two products 
do not have effectiveness signiﬁ cant differences, ustekinumab became the dominant 
